Furthermore, we isolated CD4 + and CD8 + T cells from the spleens of wild-type mice and stimulated them in culture with anti-CD3 and anti-CD28 to mimic antigenic activation. We confirmed rapid A1 ...
The intrinsic apoptotic pathway is controlled by the BCL-2 protein family. Expression of the pro-survival members, namely BCL-2, BCL-XL, BCL-W, MCL-1, BFL-1 and BCL-B, varies greatly and strongly ...
Bcl-2 family proteins are highly conserved molecules that play a crucial role in regulating the release of apoptotic proteins from mitochondria. They possess Bcl-2 homology (BH) domains, which are ...
Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma ...
New York, USA, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Game-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsight DelveInsight’s BCL-2 Inhibitor Market Insights report ...
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent pulmonary fibrosis and identified a promising strategy to reverse it. The ...
Use of tumor-mediated TRAIL-receptor expression to evaluate apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer. SPARC microenvironment signature (SMS) in patients ...
Pharmacodynamic-Guided Modified Continuous Reassessment Method–Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors The specific targeting of diseases, particularly cancer, is a ...
ROCKVILLE, Md. and SUZHOU, China, Nov. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to ...
BUFFALO, NY- September 1, 2022 – A new research paper was published in Aging ("Aging (Albany NY)" by Medline/PubMed, "Aging-US" by Web of Science) on the cover of Volume 14, Issue 16, entitled, ...
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent pulmonary fibrosis and identified a promising strategy to reverse it. The ...
Fochon Pharmaceuticals Ltd., a subsidiary of Shanghai Fosun Pharmaceutical Co. Ltd., out-licensed FCN-338, a BCL-2 inhibitor, to Eli Lilly and Co. for an up-front payment of $40 million along with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results